Acoziborole
Small molecule
Acoziborole is one of 4 small molecule programs targeting Human African Trypanosomiasis. It is currently in development.
1
Indications
4
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
8 competitors in Human African Trypanosomiasis
#DrugCompanyPhaseTrials
1Lampit
BayerPhase 3
Ornidyl
UUSWM, LLC (dba US WorldMeds)
Phase 3
Fexinidazole
SanofiPhase 3
Acoziborole
DDrugs for Neglected Diseases
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Human African Trypanosomiasis1 trial
Midazolam1 trial
Single Dose1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Acoziborole. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Company
- DDrugs for Neglected Diseases